| abstract |
Compounds of formula (I), in which: R1 represents hydrogen or C1-6 alkyl, R2 represents hydrogen, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl or C3-6 cycloalkyl, R3 represents one or more radicals selected from hydrogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, halogen, trifluoromethyl, amino, C1-6 alkylamino or di(C1-6 alkyl)amino, R4 represents one or more radicals selected from hydrogen or C1-6 alkyl, A represents hydrogen, C1-6 alkyl, COC(R5R6)N(R7R8) or COOC1-6 alkyl, R5 represents hydrogen, C1-6 alkyl, hydroxy-C1-2 alkyl, mercaptomethyl, (methylthio)C1-2 alkyl, carboxy-C1-2 alkyl, 2-(C1-3 alkoxy)ethyl, (aminocarbonyl)C1-2 alkyl, amino-C1-4 alkyl, 3-imidazolylmethyl, phenylmethyl or (4-hydroxyphenyl)-methyl, or in addition, R5 together with the adjacent nitrogen may represent a piperidine, pyrrolidine or a 2-pyrrolidinone ring, R6, R7 and R8 independently represent hydrogen or C1-6 alkyl, or in addition, R7 and R8 taken together with the nitrogen to which they are attached may represent a C4-5 N heterocyclic ring, and pharmaceutically acceptable acid addition salts thereof, are useful as pharmaceuticals; in particular they possess N-methyl-(D)-aspartate blocking properties and are useful in the treatment and/or prevention of neurological disorders. |